tsp 1

SLLK, Control Peptide for TSP1 Inhibitor acetate is a control peptide for LSKL.

LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .

SLLK is a control peptide for LSKL.

SLLK, the control peptide for the TSP1 inhibitor, serves as the counterpart to LSKL.

LSKL, INhibitor of Thrombospondin (TSP-1) is a TGF-β1 antagonist that inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis. LSKL can also inhibit subarachnoid fibrosis, prevent the occurrence of chronic hydrocephalus and improve long-term neurocognitive deficits after subarachnoid hemorrhage by inhibiting TSP-1-mediated TGF-β1 activity.

Thrombospondin-1 (TSP-1)-derived CD36 binding motif is a bioactive peptide cyclized by a disulfide bond, critical for TSP-1-CD36 interaction. Involved in cancer metastasis, tumor adhesion, and angiogenesis, this matrix-bound glycoprotein-origin peptide competitively inhibits platelet aggregation and tumor metastasis.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.

ABT-510 is synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8).

Thrombospondin-1 (1016-1023) [human, bovine, mouse], a segment of Thrombospondin-1 (TSP-1), functions as a CD47 agonist.

KRFK, a peptide originating from TSP-1, activates TGF-β and facilitates TGF-β-mediated signaling pathways, independently of thrombospondin (TSP) receptors like CD47 and CD36. This property makes KRFK a potential research tool for chronic ocular surface inflammatory disorders [1].

KRFK TFA, a TSP-1-derived peptide, activates TGF-β and enhances its associated signaling pathways independently of thrombospondin (TSP) receptors like CD47 and CD36. This compound has potential applications in research on chronic ocular surface inflammatory disorders [1].

Properdistatin, a peptide originating from the thrombospondin 1 (TSP-1) domain of properdin, exhibits angiogenesis inhibition and vascular function enhancement capabilities, showing promise for melanoma research [1].

TAX2 peptide is a novel dodecapeptide designed through molecular docking and simulation, originating from the sequence of the cell surface receptor CD47. As a selective antagonist of the TSP-1 (thrombospondin-1) and CD47 interaction, TAX2 peptide enhances the binding of TSP-1 to CD36. This disrupts the activation of VEGFR2 (vascular endothelial growth factor receptor 2), blocking downstream NO (nitric oxide) signaling and exhibiting anti-angiogenic properties. TAX2 peptide is useful for studying angiogenesis and tumor cell interactions within the tumor microenvironment.